Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: Systematic review with meta-analysis

Respiratory Medicine

Volumn 103, Issue 10, 2009, Pages 1421-1429

  Rodrigo, Gustavo J ^a   Castro Rodriguez, José A ^b   Nannini, Luís J ^c   Moral, Vicente Plaza ^d   Schiavi, Eduardo A ^e  

^a HOSPITAL CENTRAL DE LAS FUERZAS ARMADAS   (Uruguay)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Hospital Maria Ferrer   (Argentina)

Author keywords

Adverse effects; Anticholinergics; Chronic obstructive pulmonary disease; Safety; Tiotropium

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; STROKE; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; HUMANS; MYOCARDIAL INFARCTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SCOPOLAMINE DERIVATIVES; STROKE;

EID: 69449088107     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.05.020     Document Type: Article

References (39)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. http://www.goldcopd.org [accessed 03.11.08].
2. Celli B.R., and MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
3. Barnes P.J. The pharmacological properties of tiotropium. Chest 117 Suppl. 2 (2000) 63S-66S
4. Barnes P.J., Belvisi M.G., Mak J.C.W., Haddad E.B., and O'Connor B. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 56 (1995) 853-859
5. Durham M.C. Tiotropium (Spiriva): a once-daily inhaled anticholinergic medication for chronic obstructive pulmonary disease. BUMC Proc 17 (2004) 366-373
6. Gross N.J. Tiotropium bromide. Chest 126 (2004) 1946-1953
7. Barr R.G., Bourbeau J., Camargo C.A., and Ram F.S.F. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 61 (2006) 854-862
8. Rodrigo G.J., and Nannini L.J. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther 20 (2007) 495-502
9. Kesten S., Jara M., Wentworth C., and Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 130 (2006) 1695-1703
10. Lee T.A., Simon A., Pickard A.S., Au D.A., Bartle B., and Weiss K.B. Risk of death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 149 (2008) 380-390
11. Singh S., Loke Y.K., and Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. J Am Med Assoc 300 (2008) 1439-1450
12. Oba Y., Zaza T., and Thameem D.M. Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J COPD 3 (2008) 1-10
13. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008) 1543-1554
14. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 354 (1999) 1896-1900
15. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.0.1 [updated September 2008]. The Cochrane Collaboration. Available from: www.cochrane-handbook.org; 2008 [accessed 04.01.09].
16. Higgins J.P.T., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. Br Med J 327 (2003) 557-560
17. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959) 719-748
18. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
19. Altman D.G., and Bland J.M. Interaction revisited: the difference between two estimates. Br Med J 326 (2003) 219
20. Bateman E.D., van Dyk M., and Sagriotis A. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study. Pulm Pharmacol Ther 21 (2008) 20-25
21. Briggs D.D., Covelli H., Lapidus R., Bhattycharya S., Kesten S., and Casino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 18 (2005) 397-404
22. Brusasco V., Hodder R., Miravitlles M., Korducki L., Towse L., and Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58 (2003) 399-404 [published correction appears in Thorax 2005;60:105]
23. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San Pedro G., ZuWallack R.L., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
24. Casaburi R., Kukafka D., Cooper C.B., Witek T.J., and Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 127 (2005) 809-817
25. Chan C.K., Maltais F., Sigouin C., Haddon J.M., and Ford G.M. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J 14 (2007) 465-472
26. Covelli H., Sudipta M.D., Bhattacharya S., Cassino C., Conoscenti C., and Kesten S. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy 25 (2005) 1708-1718
27. Criner G.J., Sharafkhaneh A., Player R., Conoscenti C.S., Johnson P., Keyser M.T., et al. Efficacy of tiotropium inhalation powder in African-American patients with chronic obstructive pulmonary disease. J Chron Obstruct Pulm Dis 5 (2008) 35-541
28. Dusser D., Bravo M.L., and Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 27 (2006) 547-555 [published correction appears in Eur Respir J 2006;27:1076]
29. 1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther 21 (2008) 146-151
30. Niewoehner D.E., Rice K., Cote C., Paulson D., Cooper A.D., Korducki L., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. A randomized trial. Ann Intern Med 143 (2005) 317-326
31. Powrie D.J., Wilkinson T.M.A., Donaldson G.C., Jones P., Scrine K., Viel K., et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 30 (2007) 472-478
32. Boehringer Ingelheim Trials Register. Spiriva 205-250 trial. http://trials.boehringer-ingelheim.com/com/Home/TrialResults/TrialDetail /index.jsp [accessed on 03.11.07].
33. Boehringer Ingelheim Trials Register. Spiriva 205-257 trial. http://trials.boehringer-ngelheim.com/com/Home/TrialResults/TrialDetail/ index.jsp. [accessed on 03.11.07].
34. Tonnel A.B., Perez T., Grosbois J.M., Verkindre C., Bravo ML., and Brun M. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J COPD 3 (2008) 301-310
35. Vogelmeir C., Kardos P., Harari S., Gans S.J., Stenglein S., and Thirlwell J. Formoterol mono-and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 102 (2008) 1511-1520
36. Voshaar T., Lapidus R., Maleki-Yazdi R., Timmer W., Rubin E., Lowe L., et al. A randomized study of tiotropium Respimats Soft Mist™ Inhaler vs. ipratropium pMDI in COPD. Respir Med 102 (2008) 32-41
37. Wedzicha J.A., Calverley P.M.A., Seemungal T.A., Hagan G., Ansari Z., and Stockley R.A. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177 (2008) 19-26
38. Casaburi R., Briggs Jr. D.D., Donohue J.F., Serby Ch.W., Menjoge S.S., and Witek Jr. T.J. The spirometric efficacy on once-daily dosing with tiotropium in stable COPD. A 13-week multicenter trial. Chest 118 (2000) 1294-1302
39. Donohue J.F., van Noord J.A., Bateman E.D., Langley S.J., Lee A., Witek T.J., et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122 (2002) 47-55